Loading...

RVPH REVIVA PHARMACEUTICALS HOLDINGS INC Expansion Plans 8-K Filing

RVV

RVPH

REVIVA PHARMACEUTICALS HOLDINGS INC

(RVPH)

2024 8-K

Financial Results Report

Stock Offering Announcement

Stock Split Announcement

Compliance Exception Granted

Stock Changes Approval

Financial Results Update

Listing Compliance Update

Bylaw Amendment

Stock Offering Details

Financial Results Update

Equity Offerings

Product Expansion

Equity Offerings

Financial Statements

Financial Results

Executive Compensation

Positive Trial Results

Financial Results

Enrollment Update

Executive Bonuses

Capital Raise Update

Financial Results

Securities Purchase Agreement

Enrollment Update for RECOV...

Financial Results

FDA Alignment for Phase 3 P...

Financial Results

Restatement of Financial St...

Securities Purchase Agreement

Financial Results

Change of Accountant

Enrollment Completion in Ph...

Financial Results

Management Changes

Phase 3 RECOVER study updat...

Financial Disclosure

Financial Results Disclosure

External Links:

Reviva Pharmaceuticals announced alignment with the FDA for its Phase 3 program for brilaroxazine in schizophrenia, with plans to initiate clinical trials and complete NDA submission requirements by Q3 2025.

AI Assistant

REVIVA PHARMACEUTICALS HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.